Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 6/20 | 0.47 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.47 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.47 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.38 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7699375 | 0.87 | KCNH2 (0.49) | KCNH2CACNA1FCHRM2ACHEAGTR1 | |
| SCHEMBL7697484 | 0.87 | KCNH2 (0.49) | KCNH2CACNA1FCHRM2ACHEAGTR1 | |
| SCHEMBL7697481 | 0.87 | KCNH2 (0.49) | KCNH2CACNA1FCHRM2ACHEAGTR1 | |
| Hydrochloric Acid SCHEMBL7701103 | 0.86 | KCNH2 (0.48) | KCNH2CACNA1FCHRM2ACHEAGTR1 | |
| Hydrochloric Acid SCHEMBL7696256 | 0.86 | KCNH2 (0.48) | KCNH2CACNA1FCHRM2ACHEAGTR1 | |
| Hydrochloric Acid SCHEMBL7696254 | 0.86 | KCNH2 (0.48) | KCNH2CACNA1FCHRM2ACHEAGTR1 | |
| Hydrochloric Acid SCHEMBL7700691 | 0.83 | KCNH2 (0.48) | KCNH2CACNA1FCHRM2ACHEAGTR1 | |
| Hydrochloric Acid SCHEMBL7701317 | 0.83 | KCNH2 (0.47) | KCNH2CACNA1FCHRM2ACHEAGTR1 | |
| Hydrochloric Acid SCHEMBL7702535 | 0.82 | KCNH2 (0.47) | KCNH2CACNA1FCHRM2ACHEAGTR1 | |
| SCHEMBL2008747 | 0.79 | ADRB2 (0.51) | KCNH2ADRB2ADRB1ADRB3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362062-B2 | Pharmaceutical compositions with improved dissolution | MCNEIL-PPC, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| EP-2339328-A2 | Pharmaceutical co-crystal compositions of celecoxib | Transform Pharmaceuticals, Inc. (US) | 2011-06-29 | — | — | EP | disclosed |
| US-20060134198-A1 | Pharmaceutical compositions with improved dissolution | JOHNSON & JOHNSON CONSUMER INC. | 2006-06-22 | — | — | US | disclosed |
| US-20060052432-A1 | Pharmaceutical compositions with improved dissolution | TRANSFORM PHARMACEUTICALS, INC. | 2006-03-09 | — | — | US | disclosed |
| EP-1579198-A1 | PHARMACEUTICAL COMPOSITIONS WITH IMPROVED DISSOLUTION | Transform Pharmaceuticals, Inc. (US) | 2005-09-28 | — | — | EP | disclosed |
| EP-1515703-A1 | PHARMACEUTICAL COMPOSITIONS WITH IMPROVED DISSOLUTION | Transform Pharmaceuticals, Inc. (US) | 2005-03-23 | — | — | EP | disclosed |
| US-20050025791-A1 | Pharmaceutical compositions with improved dissolution | TRANSFORM PHARMACEUTICALS, INC. | 2005-02-03 | — | — | US | disclosed |
| EP-1446118-A1 | ORAL DOSAGE FORM OF A SULFONAMIDE PRODRUG SUCH AS PARECOXIB | Pharmacia Corporation (US) | 2004-08-18 | — | — | EP | disclosed |
| WO-2004061433-A1 | PHARMACEUTICAL COMPOSITIONS WITH IMPROVED DISSOLUTION | TRANSFORM PHARMACEUTICALS, INC. (US) | 2004-07-22 | — | — | WO | disclosed |
| WO-2004026235-A2 | PHARMACEUTICAL COMPOSITIONS WITH IMPROVED DISSOLUTION | TRANSFORM PHARMACEUTICALS, INC. (US) | 2004-04-01 | — | — | WO | disclosed |
| WO-2004000284-A1 | PHARMACEUTICAL COMPOSITIONS WITH IMPROVED DISSOLUTION | TRANSFORM PHARMACEUTICALS, INC. (US) | 2003-12-31 | — | — | WO | disclosed |
| US-20030100595-A1 | Oral dosage form of a sulfonamide prodrug | PHARMACIA CORPORATION | 2003-05-29 | — | — | US | disclosed |
| WO-2003041705-A1 | ORAL DOSAGE FORM OF A SULFONAMIDE PRODRUG SUCH AS PARECOXIB | PHARMACIA CORPORATION (US) | 2003-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050025791-A1 | Pharmaceutical compositions with improved dissolution | ABCG2, SI, SLC10A2 | KCNH2 4575/4885CACNA1F 1742/4885CHRM2 2561/4885 |
| US-20030100595-A1 | Oral dosage form of a sulfonamide prodrug | PTGS2, PTGES2, SI | KCNH2 3986/4885CACNA1F 1979/4885CHRM2 3821/4885 |
| US-20060052432-A1 | Pharmaceutical compositions with improved dissolution | ABCG2, SI, SLC10A2 | KCNH2 4449/4885CACNA1F 1683/4885CHRM2 2306/4885 |
| US-20060134198-A1 | Pharmaceutical compositions with improved dissolution | ABCG2, SI, SLC10A2 | KCNH2 4449/4885CACNA1F 1683/4885CHRM2 2306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.